表观遗传学药物：癌症治疗中的靶向表观遗传标记。
Epidrugs: targeting epigenetic marks in cancer treatment.
机构信息
Department of Surgery, Drug Research and Development Center, Federal University of Ceara , Fortaleza , Brazil.
Department of Physiology and Pharmacology, Drug Research and Development Center, Federal University of Ceara , Fortaleza , Brazil.
出版信息
Epigenetics. 2019 Dec;14(12):1164-1176. doi: 10.1080/15592294.2019.1640546. Epub 2019 Jul 13.
Abstract
Growing evidence suggests that aberrant epigenetic regulation of gene function is strongly related to the genesis of cancer. Unlike genetic mutations, the ability to reprogram the epigenetic landscape in the cancer epigenome is one of the most promising target therapies in both treatment and reversibility of drug resistance. Epigenetic alterations in cancer development and progression may be the basis for the individual variation in drug response. Thus, this review focuses on the emerging area of pharmaco(epi)genomics, specifically highlighting epigenetic reprogramming during tumorigenesis and how epigenetic markers are targeted as a therapy (epidrugs) and the clinical implications of this for cancer treatment.
摘要
越来越多的证据表明，基因功能的表观遗传调控失常与癌症的发生密切相关。与基因突变不同，在癌症表观基因组中重新编程表观遗传景观的能力是治疗和逆转耐药性最有前途的靶向治疗之一。癌症发生和发展中的表观遗传改变可能是药物反应个体差异的基础。因此，本综述侧重于药物基因组学（epi）的新兴领域，特别是强调肿瘤发生过程中的表观遗传重编程，以及如何将表观遗传标记作为一种治疗方法（epidrugs）进行靶向治疗，以及这对癌症治疗的临床意义。
相似文献
1
Epidrugs: targeting epigenetic marks in cancer treatment.
Epigenetics. 2019 Dec;14(12):1164-1176. doi: 10.1080/15592294.2019.1640546. Epub 2019 Jul 13.
2
Cancer epigenetics: Moving forward.
PLoS Genet. 2018 Jun 7;14(6):e1007362. doi: 10.1371/journal.pgen.1007362. eCollection 2018 Jun.
3
Towards a more precise therapy in cancer: Exploring epigenetic complexity.
Curr Opin Chem Biol. 2020 Aug;57:41-49. doi: 10.1016/j.cbpa.2020.04.008. Epub 2020 May 29.
4
Targeting the epigenetic regulation of antitumour immunity.
Nat Rev Drug Discov. 2020 Nov;19(11):776-800. doi: 10.1038/s41573-020-0077-5. Epub 2020 Sep 14.
5
Targeting Epigenetics in Cancer.
Annu Rev Pharmacol Toxicol. 2018 Jan 6;58:187-207. doi: 10.1146/annurev-pharmtox-010716-105106. Epub 2017 Oct 6.
6
Pharmacological targeting of the cancer epigenome.
Nat Cancer. 2024 Jun;5(6):844-865. doi: 10.1038/s43018-024-00777-2. Epub 2024 Jun 27.
7
Epigenetic protein complexes: the adequate candidates for the use of a new generation of epidrugs in personalized and precision medicine in cancer.
Epigenomics. 2020 Jan;12(2):171-177. doi: 10.2217/epi-2019-0169. Epub 2019 Dec 18.
8
Pharmacoepigenetics: an element of personalized therapy?
Expert Opin Drug Metab Toxicol. 2017 Apr;13(4):387-398. doi: 10.1080/17425255.2017.1260546. Epub 2016 Nov 28.
9
New Promises to Cure Cancer and Other Genetic Diseases/Disorders: Epi-drugs Through Epigenetics.
Curr Top Med Chem. 2019;19(12):972-994. doi: 10.2174/1568026619666190603094439.
10
Paediatric Strategy Forum for medicinal product development of epigenetic modifiers for children: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.
Eur J Cancer. 2020 Nov;139:135-148. doi: 10.1016/j.ejca.2020.08.014. Epub 2020 Sep 26.
引用本文的文献
1
Research progress on the diagnostic value of fecal calprotectin in colorectal tumors.
Front Med (Lausanne). 2025 Jul 9;12:1626197. doi: 10.3389/fmed.2025.1626197. eCollection 2025.
2
Novel quinazoline-triazole-based -hydroxybenzamides/-hydroxypropenamides as HDAC inhibitors: design, synthesis, biological evaluation, and docking studies.
RSC Adv. 2025 Jul 22;15(32):26201-26215. doi: 10.1039/d5ra04193g. eCollection 2025 Jul 21.
3
Cancer-Associated Genetic Aberrations and Precision Medicine.
Int J Med Sci. 2025 Jun 12;22(12):2932-2943. doi: 10.7150/ijms.109506. eCollection 2025.
4
CEBPD regulates CD47 and MAP4K4 via chromatin accessibility in canine mammary tumor monocytes.
Sci Rep. 2025 Jul 2;15(1):23404. doi: 10.1038/s41598-025-06296-z.
5
Tranylcypromine-Based LSD1 Inhibitors as Useful Agents to Reduce Viability of .
ACS Infect Dis. 2025 Aug 8;11(8):2178-2189. doi: 10.1021/acsinfecdis.5c00224. Epub 2025 Jul 2.
6
Structural characteristics and SARs of EZH2 inhibitors.
Mol Divers. 2025 Jul 1. doi: 10.1007/s11030-025-11272-w.
7
Systematic analysis of the aberrances and functional implications of epigenetic genes in hepatocellular carcinoma.
Discov Oncol. 2025 May 27;16(1):936. doi: 10.1007/s12672-025-02765-z.
8
Intimate partner violence and stress-related disorders: from epigenomics to resilience.
Front Glob Womens Health. 2025 May 12;6:1536169. doi: 10.3389/fgwh.2025.1536169. eCollection 2025.
9
Drug Discovery for Histone Deacetylase Inhibition: Past, Present and Future of Zinc-Binding Groups.
Pharmaceuticals (Basel). 2025 Apr 16;18(4):577. doi: 10.3390/ph18040577.
10
Epigenetic implications in the pathogenesis of corticotroph tumors.
Pituitary. 2025 Apr 21;28(3):51. doi: 10.1007/s11102-025-01522-3.
本文引用的文献
1
Targeting epigenetics for cancer therapy.
Arch Pharm Res. 2019 Feb;42(2):159-170. doi: 10.1007/s12272-019-01126-z. Epub 2019 Feb 26.
2
Strategies for first-line immunotherapy in squamous cell lung cancer: are combinations a game changer?
Transl Lung Cancer Res. 2018 Sep;7(Suppl 3):S198-S201. doi: 10.21037/tlcr.2018.07.02.
3
N-methyladenine DNA Modification in Glioblastoma.
Cell. 2018 Nov 15;175(5):1228-1243.e20. doi: 10.1016/j.cell.2018.10.006. Epub 2018 Nov 1.
4
Monoclonal antibodies in cancer immunotherapy.
Mol Biol Rep. 2018 Dec;45(6):2935-2940. doi: 10.1007/s11033-018-4427-x. Epub 2018 Oct 11.
5
Epigenetics and Epi-miRNAs: Potential markers/therapeutics in leukemia.
Biomed Pharmacother. 2018 Oct;106:1668-1677. doi: 10.1016/j.biopha.2018.07.133. Epub 2018 Jul 29.
6
Downregulated microRNAs in the colorectal cancer: diagnostic and therapeutic perspectives.
BMB Rep. 2018 Nov;51(11):563-571. doi: 10.5483/BMBRep.2018.51.11.116.
7
Unveiling epigenetic regulation in cancer, aging, and rejuvenation with in vivo reprogramming technology.
Cancer Sci. 2018 Sep;109(9):2641-2650. doi: 10.1111/cas.13731. Epub 2018 Aug 15.
8
The causal relationship between epigenetic abnormality and cancer development: in vivo reprogramming and its future application.
Proc Jpn Acad Ser B Phys Biol Sci. 2018;94(6):235-247. doi: 10.2183/pjab.94.016.
9
Pharmacological Targeting of Cell Cycle, Apoptotic and Cell Adhesion Signaling Pathways Implicated in Chemoresistance of Cancer Cells.
Int J Mol Sci. 2018 Jun 6;19(6):1690. doi: 10.3390/ijms19061690.
10
Association between H3K4 methylation and cancer prognosis: A meta-analysis.
Thorac Cancer. 2018 Jul;9(7):794-799. doi: 10.1111/1759-7714.12647. Epub 2018 May 8.
Zotero 插件